darren moore foxo4-dri NVON Darren Moore - Head of

PHASE III DUAL USE APPLICATIONS Phase III Dual use applications (Commercial DoD/Military): Phase III work will be oriented towards transition and commercialization of the developed Advance Enabling High Speed Technologies

Results tracked at 4, 8, and 12 weeks

Topical KPV targets localized skin inflammation: eczema, rosacea, post-procedure redness, and wound healing

Titanium dioxide nanoparticles increase superoxide anion production by acting on NADPH oxidase

M., Mercola, M., & Wood, E

Its long-acting profile delivers smooth, durable signaling across the research window, and it is frequently studied in combination with GLP-1 agonists, where the two pathways are explored for their complementary effects on satiety and metabolic balance